Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | USP7 | Q93009 | 12/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11716876 | 0.84 | USP7 (0.42) | NOS2NOS3USP7DHFR | |
| SCHEMBL2904338 | 0.79 | NOS3 (0.36) | NOS2NOS3USP7DHFRNOS1 | |
| SCHEMBL30019041 | 0.77 | NOS2 (0.44) | NOS2NOS3USP7DHFRNOS1 | |
| SCHEMBL22589902 | 0.76 | NOS3 (0.35) | NOS2NOS3USP7DHFR | |
| SCHEMBL5200520 | 0.73 | USP7 (0.43) | NOS2NOS3USP7 | |
| SCHEMBL14127760 | 0.73 | TLR8 (0.42) | NOS2NOS3 | |
| SCHEMBL20343528 | 0.72 | NOS2 (0.52) | NOS2NOS3USP7DHFR | |
| SCHEMBL23556098 | 0.70 | NOS3 (0.37) | NOS2NOS3USP7NOS1UHRF1 | |
| SCHEMBL25767334 | 0.70 | NOS2 (0.46) | NOS2NOS3USP7DHFRNOS1 | |
| SCHEMBL28257265 | 0.70 | NOS3 (0.36) | NOS2NOS3USP7DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066377-B | Novel phenylimidazopyrazines | HOFFMANN LA ROCHE | 2014-11-19 | — | — | CN | disclosed |
| EP-2307418-B1 | NOVEL PHENYLIMIDAZOPYRAZINES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-102066377-A | Novel phenylimidazopyrazines | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| EP-2307418-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101316844-A | Inhibitors of diacylglycerol acyltransferase (DGAT) | HOFFMANN LA ROCHE (CH) | 2008-12-03 | — | — | CN | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1551813-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
| EP-1551813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1268437-A1 | INHIBITORS OF PROTEIN KINASES | Knoll GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002030908-A1 | INHIBITORS OF PROTEIN KINASES | KNOLL GMBH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | NOS2 2858/4885NOS3 3272/4885USP7 2779/4885 |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | NOS2 1981/4885NOS3 1970/4885USP7 2924/4885 |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | NOS2 2858/4885NOS3 3272/4885USP7 2779/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | NOS2 2858/4885NOS3 3272/4885USP7 2779/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | NOS2 1981/4885NOS3 1970/4885USP7 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.